推荐文章
更多- High-salt-driven gut microbiota dysfunction aggravates prostatitis by promoting AHR/SGK1/FOXO1 axis-mediated Th17 cell differentiation
- Motor protein KIF13B orchestrates hepatic metabolism to prevent metabolic dysfunction-associated fatty liver disease
- Clinical-transcriptomic classification of lumbar disc degeneration enhanced by machine learning
快捷入口
作者投稿
编辑办公
- 最新文章
EDITORIAL
Plague – an infectious disease challenge far from resolved AI导读
Hagen Frickmann, Dorothea Franziska Wiemer, Jonas Schmidt-Chanasit当前状态:一校优先2026 DOI: 10.1016/j.mmr.2026.100078RESEARCH
Trends and future projections of Parkinson’s disease burden in China: findings from the Global Burden of Disease Study 2023 AI导读
Zhe Zhao, Ai-Nan Jia, Wen Ma, Xiao-Hui Xu, Mai-Geng Zhou, Jun-Liang Yuan当前状态:一校优先2026 DOI: 10.1016/j.mmr.2026.100077摘要:Background:Parkinson’s disease (PD) is a major public health burden in China. We aimed to analyze temporal trends in PD burden across China from 1990 to 2023 and project the future burden through 2050.Methods:Using data from the 2023 Global Burden of Disease (GBD 2023) database, prevalence, incidence, deaths, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) of PD in 31 provinces, autonomous regions, municipalities, and the two special administrative regions (SAR) of Hong Kong and Macao of China from 1990 to 2023 were analyzed. Age-standardized rates (ASR) and the average annual percent change (AAPC) were calculated. Changes in case numbers were decomposed using a Das Gupta framework, and future burden to 2050 was projected using a probabilistic model-averaging approach.Results:From 1990 to 2023, the age-standardized prevalence, incidence, and YLD rates of PD increased in China, whereas the age-standardized mortality, YLL, and DALY rates decreased. The number of people living with PD increased from 781.29 thousand (95% UI 629.39–973.58) in 1990 to 3445.69 thousand (95% UI 2804.28–4243.67) in 2023, and incident cases increased from 99.51 thousand (95% UI 82.51–118.00) in 1990 to 379.69 thousand (95% UI 319.28–447.58) in 2023. The age-standardized prevalence rate increased from 106.56 per 100,000 (95% UI 86.16–131.29) to 148.74 per 100,000 (95% UI 122.07–183.52) (AAPC=1.03%, 95% CI 0.98–1.09), whereas the age-standardized mortality, DALY, and YLL rates decreased from 4.69 per 100,000 to 3.78 per 100,000, 92.40 per 100,000 to 77.87 per 100,000, and 77.37 per 100,000 to 56.81 per 100,000, respectively. The age-standardized YLD rate increased from 15.03 per 100,000 to 21.07 per 100,000. Males had consistently higher age-standardized rates than females, although the prevalence rate increased faster in females than in males (AAPC: 1.14% vs. 0.86%, P<0.001). In 2023, PD prevalence increased with age, whereas incident cases peaked at ages 70–74 years and deaths at ages 80–84 years. High-middle-Socio-demographic Index (SDI) regions had the highest age-standardized prevalence rate (150.53 per 100,000), while low-SDI regions had the lowest (140.26 per 100,000), with relatively faster increases in low- and low-middle-SDI regions. The highest age-standardized prevalence and incidence rates were observed in Tianjin, Liaoning, Xinjiang, and Hainan. Besides, mortality decreased from 1990 to 2023 in all provinces except Hebei and Jiangsu. In decomposition analyses, changes in age-specific rates contributed most to increases in prevalent and incident cases, whereas population aging contributed most to changes in deaths, DALYs, YLLs, and YLDs. By 2050, the numbers of prevalent cases, incident cases, deaths, and DALYs were projected to reach 6891.38 thousand, 759.37 thousand, 91.66 thousand, and 2528.54 thousand, respectively. In addition, age-standardized prevalence and incidence rates were projected to increase, whereas age-standardized mortality and DALY rates were projected to decrease.Conclusions:From 1990 to 2023, China experienced a substantial increase in PD burden accompanied by a shift toward a disability-dominated burden, characterized by rising age-standardized prevalence, incidence, and YLDs, but declining mortality and YLLs. Projections through 2050 indicate that population aging will remain the primary driver of future increases in PD burden, underscoring the need for strengthened long-term care, rehabilitation, and region-specific prevention strategies.26
5
0
2026-11-13
EDITORIAL
RESEARCH
Matrix-stiffness-triggered mechanotransduction fuels hepatocellular carcinoma proliferation through Hippo-orchestrated ANKRD1-PRMT5 complex-driven arginine methylome remodelling AI导读
Jia-Cheng Huang, Bao-Dong Chen, Yuan Xu, Si-Jie Zheng, Yi-Qing Hu, Cai-Xu Pan, Li-Zhu Zhu, Ying Chi, Meng-Lan Wang, Fei Wang, Yi-Xin Hua, Peng-Yu Gong, Jian-Xiang Chen, Shu-Sen Zheng, Yi-Ting Qiao当前状态:一校优先2026 DOI: 10.1016/j.mmr.2026.100075摘要:Background:Stiffened extracellular matrix is a primary risk factor for hepatocellular carcinoma (HCC). We aim to investigate the mechanism by which matrix stiffness promotes malignant proliferation and develop an experimental therapeutic strategy for HCC.Methods:CCl4-induced and ATP-binding cassette subfamily B member 4 (Abcb4–/–) spontaneous liver-fibrosis mouse models were used to validate the tumour-promoting effect of matrix stiffness in HCC. Polyacrylamide gel was used to simulate matrix with varying stiffness. RNA sequencing (RNA-seq), in vitro proliferation assays, and in vivo tumour models were used to elucidate the role of mechanically responsive protein ankyrin repeat domain protein 1(ANKRD1) in HCC. Biochemical assays were performed to reveal the interaction between ANKRD1 and protein arginine methyltransferase 5 (PRMT5). Chromatin immunoprecipitation and luciferase reporter assays were performed to confirm the pattern of transcriptional regulation. The anti-tumour efficiency of Hippo pathway inhibitors and the PRMT5 inhibitor was evaluated in vitro and in vivo.Results:Analysis of human hepatic fibrosis index, fibrotic mice bearing HCC, and polyacrylamide gel-based soft matrix culture model demonstrated that a stiff microenvironment promoted HCC progression. RNA-seq of HCC cells cultured on varying stiffness conditions identified ANKRD1 as a target for mechanical signaling, which was further validated in human HCC tissue samples at both RNA and protein levels. Gene function analysis revealed that ANKRD1 promoted HCC progression, which partially mediated stiffness-associated malignant proliferation. Mechanistically, protein-protein interaction assays and quantitative post-translational modification assays proved the interaction between the C-terminus of ANKRD1 and PRMT5, which promoted the cytoplasmic localization of PRMT5 and arginine methylome remodelling. Furthermore, inhibitors of the Hippo pathway decreased ANKRD1 expression and sensitized HCC cells to PRMT5 inhibitor LLY-283 in both an in vitro cytotoxicity assay and a murine fibrotic HCC model.Conclusions:ANKRD1 is a mechanically responsive protein that promotes the proliferation of HCC cells by regulating PRMT5 activity. The combination of Yes1-associated transcriptional regulator/tafazzin (YAP/TAZ) inhibitors and a PRMT5 inhibitor is a potential therapeutic strategy for HCC patients with a stiffened tumour microenvironment.21
12
0
2026-11-13
LETTER TO THE EDITOR
EDITORIAL
过刊浏览






RESEARCH
Minjin Jeong, Lucas G. Vattino, Maja Djurisic, Kevin P. Rose, Hiroshi Hyakusoku, Svetolik Spasic, Xiao-Jie Ma, Hiroaki Mohri, Ronna Hertzano, Anne E. Takesian, Konstantina M. Stankovic
2026, 13(9): 1377-1398. DOI: 10.1016/j.mmr.2026.100008关键词:Spiral ganglion neurons (SGNs);Human induced pluripotent stem cells (hiPSCs);Auditory neurons;cochlea;Inner ear<HTML><网络PDF><Meta-XML><引用本文><批量引用>72
72
0
RESEARCH
Chen-Ran Wang, Ren-Da Li, Pan Wang, Xue-Si Dong, Hao Zhang, Qing-Peng Zeng, Jia-Xin Xie, Zi-Lin Luo, Xiao-Lu Chen, Ya-Di Zheng, Ji-Bin Li, Yong-Jie Xu, Fei Wang, Ni Li, Feng-Wei Tan, Jie He
2026, 13(9): 1399-1416. DOI: 10.1016/j.mmr.2026.100020关键词:lung cancer;Screening eligibility;US Preventive Services Task Force (VSPSTF) criteria;Real-world evidence<HTML><网络PDF><Meta-XML><引用本文><批量引用>32
78
0
RESEARCH
Zi-Chao Li, Yi-Fu Zhu, Ya-Juan Song, Zhi-Jun Tan, Bin Liu, Yan Jiang, Hou-An Xiao, Dong-Mei Zu, Tong Wang, Yi Shi, Yan Jiao, Xue-Yong Li, Xing-Bo Xu, Lei Shang, Zhou Yu, Bao-Qiang Song
2026, 13(9): 1417-1440. DOI: 10.1016/j.mmr.2026.100021关键词:All-trans retinoic acid (ATRA);Randomized controlled trial (RCT);Glucose metabolic reprogramming;Myofibroblast activation;hypertrophic scar<HTML><网络PDF><Meta-XML><引用本文><批量引用>104
78
0
RESEARCH
Le-Yang Wu, Jia-Hui Qiu, Xin-Yue Qiao, Lin Li, Li-Yuan Qiao, Chen-Yang Li, Ying Sun, Shu-Hui Zhang, Zeng-Zheng Du, Xiao-Yao Chang, Cheng Cheng, Bo-Hao Wang, Yi-Han Xiao, Lin Lin, Zi-Chun Hua
2026, 13(9): 1441-1461. DOI: 10.1016/j.mmr.2026.100030关键词:Microbial therapeutics;Chemical biological modification;Quorum-sensing (QS);Tumor-targeted delivery;Immune activation<HTML><网络PDF><Meta-XML><引用本文><批量引用>77
60
0
RESEARCH
Shao-Yu Liu, Shao-Kang Xu, Jing-Li Gao, Xiao-Ke Kong, Jian Shi, Ya Miao, Yi-Ting Tang, Bin Zhao, Fang Fang, Ai-Tian Wang, Shou-Ling Wu, Jia-Qi Huang, Ben Lu
2026, 13(9): 1462-1478. DOI: 10.1016/j.mmr.2026.100031关键词:Metabolic syndrome (MetS);sepsis;Inflammation;Mortality;UK Biobank;Kailuan Study<HTML><网络PDF><Meta-XML><引用本文><批量引用>76
62
0
REVIEW
Noor Obaidi, Olivia Agee, Irene Yau, Robert Moritz, Kristo Nuutila
2026, 13(9): 1479-1492. DOI: 10.1016/j.mmr.2026.100007关键词:Cold weather injury;Frostbite;Field care of frostbite;Military medicine<HTML><网络PDF><Meta-XML><引用本文><批量引用>84
61
0
REVIEW
Yan-Hong Jiang, Xing-Juan Li, De-Cao Ma, Yong-Lin Chen, Yi-Yu Shi, Yang Lu, Ren-Fang Mao
2026, 13(9): 1493-1514. DOI: 10.1016/j.mmr.2026.100013关键词:sepsis;Endothelial dysfunction;Vascular permeability;Glycocalyx injury;Therapeutic strategies<HTML><网络PDF><Meta-XML><引用本文><批量引用>93
71
0
REVIEW
Zi-Jun Ma, Jun Chen, Chen-Xi Yang, Shun-Ping Lin, Quan Gong, Zachary Braunstein, Ying-Ying Wei, Xiao-Quan Rao, Ji-Xin Zhong
2026, 13(9): 1515-1542. DOI: 10.1016/j.mmr.2026.100015关键词:Autoimmune diseases (AIDs);pregnancy;Immune microenvironment;Maternal-fetal immune adaptation;Clinical management<HTML><网络PDF><Meta-XML><引用本文><批量引用>57
50
0
LETTER TO THE EDITOR
Li Li, Qi Han, Hao-Lei Bai, Qin Xiao, Xie He, Jia-Fei Chen, Zhi-Ming Zhen, Xue-Qin Luo, Yuan-Jing Zhang, Min-Min Lu, Xiao Wang, Shi-Yin Li, Jia-Xiang Xiong, Yun Wang, Zhi-An Hu, Xiao-Long Zhang, Yong Liu, Chao He
2026, 13(9): 1543-1546. DOI: 10.1016/j.mmr.2026.100035关键词:Neuropathic pain;Sleep disorders;Sleep fragmentation;Mediodorsal thalamus;Temporoparietal desynchronization<HTML><网络PDF><Meta-XML><引用本文><批量引用>68
60
0
COMMENTARY
关键词:Exosomes;Trace element;Diabetic foot ulcers;Stimuli-responsive hydrogel<HTML><网络PDF><Meta-XML><引用本文><批量引用>59
66
0
- 征稿通知
Informatics and Artificial Intelligence for Holistic Integrative Oncology
2025-07-03 16:51:41Cancer Biomarkers for Precision Oncology
2025-07-03 16:57:37New Biological Functional Materials for Trauma Medicine
2023-03-20 10:23:57Severe Torso Trauma
2023-03-20 10:40:50
- 推荐文章
- Informatics and Artificial Intelligence for Holistic Integrative Oncology
- New Biological Functional Materials for Trauma Medicine
- Microbiome
- COVID-19
- Diagnosis and treatment of heat stroke
- Tissue Engineering and Regenerative Medicine
- Severe Torso Trauma: Epidemiology, Diagnosis, Rescue and Management
- Sepsis and Septic Shock
- Post-Traumatic Stress Disorder (PTSD)
Yong-Jie Xu, Jian-Feng Xu, Chang-Fa Xia, Yu-Jie Wu, Dian-Ge Li, Tie-Yan Liu, Huai-Ping Cui, Jin Zhang, Liang Shang, Wan-Qing Chen182|16|0
Yu-Chang Zhou, Jiang-Mei Liu, Zhen-Ping Zhao, Mai-Geng Zhou, Marie Ng138|158|0
03Nanobodies in biomedicine: from molecular characteristics to fabrication and clinical translation
Cheng-Kun Cao, Xin-Yi Xu, Fei Liang, Min Yao, Yuan-Yuan Chen, Xiao-Kun Li, Zhi-Jian Su97|62|0
Yun-Bo He, Jiao Hu, Zhi Liu, Zi-Cheng Xiao, Jin-Hui Liu, Hai-Su Liang, Wen-Zhi Deng, Zhi-Wei Li, Jun Zhang, Jia-Quan Long, Ning Gao, Bin Huang, Xi Guo, Zhen-Yu Ou, Jin-Bo Chen, Pei-Hua Liu, Min-Feng Chen, Hui-Huang Li, Rui-Zhe Wang, Xiao Guan, Shi-Yu Tong, Yang-Le Li, Wei He, Yan-Hua Zhao, Zhi-Yong Cai, Yu Gan, Cheng Zhao, Yu Cui, Yuan-Qing Dai, Yi Cai, Zhen-Yu Nie, Wei-Min Zhou, Bo-Han Zhou, Ming-Hui Hu, Ben-Yi Fan, Ding-Shan Deng, Xiong-Bing Zu93|100|0
Li-Ting Deng, Huan Yang, Xu-Fei Zhang, Ze-Xing Lin, Ni Kuang, Hai-Yang Jiang, Pei-Zhao Liu, Yang-Guang Li, Xuan-Heng Li, Wei-Zhen Li, Chu-Jun Ni, Ming-Jie Qiu, Yue Chao, Yu-Fei Pan, Yi-Yu Yang, Ye-Ting Zhu, Yun Zhao, Jian-An Ren, Xiu-Wen Wu84|17|0
50|626|0
02Biomaterials science and surface engineering strategies for dental peri-implantitis management
104|465|0
03Applications of CRISPR-Cas9 mediated genome engineering
31|259|0
04Undergraduate nursing education in the United States
12|251|0
40|208|0

